LG Chem Launches "Utipro," a Luteal Phase Support Therapy for Infertility

Subcutaneous Injectable Progesterone Formulation

LG Chem announced on May 8 that it has launched "Utipro Injection 25mg," a treatment for infertility used as a luteal phase support therapy for women undergoing assisted reproductive technology (ART). "Utipro" is a subcutaneous (SC) injection formulated with progesterone that is designed for self-administration.

New subcutaneous injection progesterone formulation Utipro by LG Chem. LG Chem

Progesterone is a hormone that plays a crucial role in assisting embryo implantation in the uterus and in creating and maintaining a stable environment during early pregnancy. It is used during the luteal phase to supplement hormone levels that may become insufficient during the ART process.

Based on physicochemical equivalence data with already approved drugs of the same ingredient and formulation, LG Chem obtained product approval from the Ministry of Food and Drug Safety in Korea in February this year.

LG Chem plans to actively address the potential supply instability that has existed in the subcutaneous injectable progesterone market, which had previously relied solely on a single imported product, by launching "Utipro"—a product for which the company will directly manage both quality and supply.

Sung Ho Kim, Head of Specialty Care at LG Chem, stated, "With the increasing age at marriage and childbirth, demand for ART medicines in clinical settings continues to grow. We will proactively identify clinical needs in women's health and consistently provide effective therapeutic solutions to meet them."

LG Chem is also planning to hold a series of symposiums to share information on the clinical use of progesterone therapy in ART and details about "Utipro."

This content was produced with the assistance of AI translation services.